Advertisement
UK markets close in 5 hours 23 minutes

  • FTSE 100

    8,048.00
    +24.13 (+0.30%)
     

  • FTSE 250

    19,696.27
    +96.88 (+0.49%)
     

  • AIM

    752.31
    +3.13 (+0.42%)
     

  • GBP/EUR

    1.1595
    +0.0006 (+0.05%)
     

  • GBP/USD

    1.2363
    +0.0012 (+0.10%)
     

  • Bitcoin GBP

    53,532.47
    +197.55 (+0.37%)
     

  • CMC Crypto 200

    1,420.90
    +6.14 (+0.43%)
     

  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     

  • DOW

    38,239.98
    +253.58 (+0.67%)
     

  • CRUDE OIL

    81.99
    +0.09 (+0.11%)
     

  • GOLD FUTURES

    2,308.60
    -37.80 (-1.61%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     

  • DAX

    17,990.82
    +130.02 (+0.73%)
     

  • CAC 40

    8,068.93
    +28.57 (+0.36%)
     
Money:

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

Novartis appoints Merck executive as oncology chief

Reuters - UK Focus

June 2 (Reuters) - Swiss drugmaker Novartis AG (Xetra: NOT.DE - news) said it has appointed Bruno Strigini, one of Merck (Dusseldorf: 6MK.DU - news) & Co Inc's top executives, to head its oncology unit.

Novartis said Strigini, who served as the president of Merck (Other OTC: MKGAF - news) 's European and Canadian operations, was appointed with immediate effect. (http://link.reuters.com/tyk79v)

Strigini takes over from Alessandro Riva, who headed Novartis' Oncology Development and Medical Affairs division on an interim basis after the departure of Herve Hoppenot earlier in the year.

Novartis in April bought London-based GSK's oncology products for $14.5 billion plus another $1.5 billion that depends on the results of a trial in melanoma in a deal that strengthened the company's No. 2 global position in cancer.

Cancer is a particular focus for some drugmakers as novel medicines show promise by boosting the body's immune system. Drugmakers are seen stocking up their oncology pipelines as they bet that combinations of drugs will become the future of cancer care. (Reporting by Aashika Jain in Bangalore; Editing by Eric Walsh)